Crinetics Pharmaceuticals, Inc.
US ˙ NasdaqGS ˙ US22663K1079

SecurityCRNX / Crinetics Pharmaceuticals, Inc.
InstitutionCitadel Advisors Llc
ManagerKen Griffin
Latest Disclosed Ownership317,934 shares
Latest Disclosed Value $ 11,547,363
Citadel Advisors Llc ownership in CRNX / Crinetics Pharmaceuticals, Inc.

On May 15, 2026 - Citadel Advisors Llc filed a 13F-HR form disclosing ownership of 317,934 shares of Crinetics Pharmaceuticals, Inc. (US:CRNX) valued at $11,547,363 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 254,720 shares of Crinetics Pharmaceuticals, Inc.. This represents a change in shares of 24.82% during the quarter. The current value of the position is $10,466,387 USD.

Citadel Advisors Llc has a history of taking positions in derivatives of the underlying security (CRNX) in the form of stock options. The firm currently holds call options representing 18,000 of underlying shares valued at $653,760 USD and put options representing 10,200 of underlying shares valued at $370,464 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

CRNX / Crinetics Pharmaceuticals, Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 317,934 63,214 24.82 11,547 -2.61 0.0016
2026-02-17 2025-12-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 254,720 -629,787 -71.20 11,857 -67.81 0.0018
2025-11-14 2025-09-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 884,507 230,872 35.32 36,840 95.97 0.0056
2025-08-14 2025-06-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 653,635 615,084 1,595.51 18,799 1,353.83 0.0033
2025-05-15 2025-03-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 38,551 33,829 716.41 1,293 436.51 0.0002
2025-02-14 2024-12-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 4,722 -130,412 -96.51 241 -96.51 0.0000
2024-11-14 2024-09-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 135,134 13,255 10.88 6,905 26.51 0.0013
2024-08-14 2024-06-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 121,879 -49,545 -28.90 5,459 -31.98 0.0011
2024-05-15 2024-03-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 171,424 148,632 652.12 8,024 890.62 0.0015
2024-02-14 2023-12-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 22,792 -136,444 -85.69 811 -82.89 0.0002
2023-11-14 2023-09-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 159,236 -82,492 -34.13 4,736 8.73 0.0010
2023-08-14 2023-06-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 241,728 -43,867 -15.36 4,356 -5.04 0.0009
2023-05-15 2023-03-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 285,595 248,239 664.52 4,587 571.45 0.0010
2023-02-14 2022-12-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 37,356 -2,855 -7.10 684 -13.54 0.0002
2022-11-14 2022-09-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 40,211 40,211 790 0.0002
2022-08-15 2022-06-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 0 -49,839 -100.00 0 -100.00
2022-05-16 2022-03-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 49,839 -14,985 -23.12 1,094 -40.61 0.0002
2022-02-14 2021-12-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 64,824 27,605 74.17 1,842 135.25 0.0004
2021-11-15 2021-09-30 13F CRINETICS PHARMACEUTICALS IN Cmn 22663K107 37,219 -23,439 -38.64 783 -31.56 0.0002
2021-08-16 2021-06-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 60,658 60,658 1,144 0.0003
2021-05-21 2021-03-31 13F/A-1 CRINETICS PHARMACEUTICALS IN COM 22663K107 0 -46,864 -100.00 0 -100.00
2021-02-16 2020-12-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 46,864 7,762 19.85 661 7.83 0.0002
2020-11-16 2020-09-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 39,102 6,076 18.40 613 5.87 0.0002
2020-08-14 2020-06-30 13F CRINETICS PHARMACEUTICALS IN Cmn 22663K107 33,026 -2,711 -7.59 579 10.08 0.0002
2020-05-15 2020-03-31 13F CRINETICS PHARMACEUTICALS IN Cmn 22663K107 35,737 7,809 27.96 526 -24.96 0.0002
2020-02-14 2019-12-31 13F CRINETICS PHARMACEUTICALS IN Cmn 22663K107 27,928 295 1.07 701 68.51 0.0003
2019-11-14 2019-09-30 13F CRINETICS PHARMACEUTICALS IN Cmn 22663K107 27,633 15,839 134.30 416 41.02 0.0002
2019-08-14 2019-06-30 13F CRINETICS PHARMACEUTICALS IN Cmn 22663K107 11,794 11,794 295 0.0001
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-05-15 2026-03-31 13F CRINETICS PHARMACEUTICALS IN COM Call 18,000 -8.63 654 -28.79 n/a n/a n/a
2026-02-17 2025-12-31 13F CRINETICS PHARMACEUTICALS IN COM Call 19,700 -81.89 917 -79.76 n/a n/a n/a
2025-11-14 2025-09-30 13F CRINETICS PHARMACEUTICALS IN COM Call 108,800 174.06 4,532 297.11 n/a n/a n/a
2025-08-14 2025-06-30 13F CRINETICS PHARMACEUTICALS IN COM Call 39,700 115.76 1,142 84.93 n/a n/a n/a
2025-05-15 2025-03-31 13F CRINETICS PHARMACEUTICALS IN COM Call 18,400 67.27 617 9.79 n/a n/a n/a
2025-02-14 2024-12-31 13F CRINETICS PHARMACEUTICALS IN COM Call 11,000 50.68 562 50.67 n/a n/a n/a
2024-11-14 2024-09-30 13F CRINETICS PHARMACEUTICALS IN COM Call 7,300 43.14 373 63.60 n/a n/a n/a
2024-08-14 2024-06-30 13F CRINETICS PHARMACEUTICALS IN COM Call 5,100 -91.50 228 -91.88 n/a n/a n/a
2024-05-15 2024-03-31 13F CRINETICS PHARMACEUTICALS IN COM Call 60,000 135.29 2,809 209.59 n/a n/a n/a
2024-02-14 2023-12-31 13F CRINETICS PHARMACEUTICALS IN COM Call 25,500 -24.78 907 -10.02 n/a n/a n/a
2023-11-14 2023-09-30 13F CRINETICS PHARMACEUTICALS IN COM Call 33,900 2,981.82 1,008 5,205.26 n/a n/a n/a
2023-08-14 2023-06-30 13F CRINETICS PHARMACEUTICALS IN COM Call 1,100 -95.13 20 -94.75 n/a n/a n/a
2023-05-15 2023-03-31 13F CRINETICS PHARMACEUTICALS IN COM Call 22,600 882.61 363 761.90 n/a n/a n/a
2023-02-14 2022-12-31 13F CRINETICS PHARMACEUTICALS IN COM Call 2,300 -98.14 42 -98.27 n/a n/a n/a
2022-11-14 2022-09-30 13F CRINETICS PHARMACEUTICALS IN COM Call 123,500 -7.56 2,426 -2.65 n/a n/a n/a
2022-08-15 2022-06-30 13F CRINETICS PHARMACEUTICALS IN COM Call 133,600 2,492 n/a n/a n/a
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-05-15 2026-03-31 13F CRINETICS PHARMACEUTICALS IN COM Put 10,200 2.00 370 -20.43 n/a n/a n/a
2026-02-17 2025-12-31 13F CRINETICS PHARMACEUTICALS IN COM Put 10,000 -73.82 466 -70.77 n/a n/a n/a
2025-11-14 2025-09-30 13F CRINETICS PHARMACEUTICALS IN COM Put 38,200 159.86 1,591 277.01 n/a n/a n/a
2025-08-14 2025-06-30 13F CRINETICS PHARMACEUTICALS IN COM Put 14,700 26.72 423 8.48 n/a n/a n/a
2025-05-15 2025-03-31 13F CRINETICS PHARMACEUTICALS IN COM Put 11,600 52.63 389 0.26 n/a n/a n/a
2025-02-14 2024-12-31 13F CRINETICS PHARMACEUTICALS IN COM Put 7,600 -60.42 389 -60.45 n/a n/a n/a
2024-11-14 2024-09-30 13F CRINETICS PHARMACEUTICALS IN COM Put 19,200 448.57 981 528.85 n/a n/a n/a
2024-08-14 2024-06-30 13F CRINETICS PHARMACEUTICALS IN COM Put 3,500 -88.92 157 -89.45 n/a n/a n/a
2024-05-15 2024-03-31 13F CRINETICS PHARMACEUTICALS IN COM Put 31,600 206.80 1,479 304.10 n/a n/a n/a
2024-02-14 2023-12-31 13F CRINETICS PHARMACEUTICALS IN COM Put 10,300 -87.53 366 -85.10 n/a n/a n/a
2023-11-14 2023-09-30 13F CRINETICS PHARMACEUTICALS IN COM Put 82,600 1,820.93 2,457 3,089.61 n/a n/a n/a
2023-08-14 2023-06-30 13F CRINETICS PHARMACEUTICALS IN COM Put 4,300 4,200.00 77 7,600.00 n/a n/a n/a
2023-05-15 2023-03-31 13F CRINETICS PHARMACEUTICALS IN COM Put 100 -90.91 2 -95.00 n/a n/a n/a
2023-02-14 2022-12-31 13F CRINETICS PHARMACEUTICALS IN COM Put 1,100 20 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.